Rocket Lab’s Record Backlog and Defense Wins Can’t Stop a 21% Weekly Plunge as Insiders Exit
03.06.2026 - 17:05:45 | boerse-global.de
Rocket Lab delivered a standout quarter — record revenue, a bulging $2.2 billion order book, and fresh military contracts — yet the stock has shed more than a fifth of its value in just seven trading days. The sell-off has been compounded by a wave of insider share sales that took place near the stock’s peak, injecting an extra dose of uncertainty into a name already trading on extreme valuation multiples.
Director Alexander Slusky led the insider exodus, selling 60,000 shares on May 28 in two tranches — 40,000 at a weighted average of $149.10 and 20,000 at $150.00 — for total proceeds of roughly $8.96 million. The shares were held through the partnership Abalone Cove LLLP, which retains 374,675 stock. Other senior executives also cashed out: President Marvin Bradford Clevenger sold 3,500 shares at an average of $146.67, Chief Operating Officer Frank Klein disposed of 36,860 shares, and General Counsel Arjun Kampani offloaded 23,804 shares. Klein and Kampani’s transactions were executed under Rule 10b5-1 trading plans established on September 19, 2025, which typically insulate them from accusations of trading on inside knowledge. Slusky’s direct sale carries no such automatic defense.
The timing is striking. All insider sales occurred at prices between $146 and $150, far above the current level. Rocket Lab stock now changes hands at around €101.80 ($109.90 at current exchange rates), down more than 20% from its all-time peak. Just how far it has come is evident in the 52-week numbers: the stock touched a high of €133.80 on May 27 (some data sources place the peak at €129.20), while the 200-day moving average still sits 66.7% below the current price. Over the past month the shares remain 48% higher, and they have more than quadrupled over the last twelve months with a 333% gain.
The valuation debate is at the heart of the correction. According to a Barchart analysis cited in recent reports, Rocket Lab is classified as a high-risk name due to its price-to-sales ratio of 137.9, reliance on the unproven Neutron rocket program, and the insider selling itself. Such a multiple leaves virtually no margin for error. The market is effectively betting not just on near-term growth but on a flawless execution of the company’s multi-year expansion plan.
Should investors sell immediately? Or is it worth buying Rocket Lab?
On the operational side, the arguments for Rocket Lab remain compelling. First-quarter revenue hit a record $200.3 million, representing 63.5% year-over-year growth, while the GAAP gross margin came in at 38.2%. The backlog swelled to $2.2 billion, a sequential increase of 20.2%, fueled by 31 new contracts for the Electron and HASTE vehicles plus five dedicated Neutron launches. In total, the launch manifest now includes more than 70 contracted missions. For the second quarter, management expects revenue of $225 million to $240 million, a GAAP gross margin of 33% to 35%, and an adjusted EBITDA loss of $20 million to $26 million.
Defense and national security work is becoming an increasingly important pillar. Rocket Lab recently passed the System Requirements Review for the Space Development Agency’s Tracking Layer Tranche 3, a program focused on missile warning, tracking, and defense satellites. That contract is worth around $816 million, which, combined with a previous Transport Layer Beta award of roughly $515 million, brings the company’s total SDA commitments to more than $1.3 billion. Additionally, the U.S. Space Force’s Space Systems Command selected Rocket Lab to develop, build, integrate, and operate two geostationary satellites with Heimdall payloads under a $90 million contract. These wins are shifting the company’s profile from prototype provider to builder of operational spacecraft — a transition that underpins the growth narrative.
Yet the most critical catalyst — and the biggest risk — remains Neutron. The medium-lift rocket is slated for its first flight in late 2026, but any delay would be disproportionately punished given the stock’s elevated valuation. Investors also worry about potential dilution: a recent prospectus supplement authorizes share sales through brokers without a fixed number or dollar amount, with commissions of up to 2.0% of the sale price. Rocket Lab warns in its own filings that such expenses could dilute earnings per share and weigh on the stock.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
With the shares now 21% below their recent high, the next major test will come in August when the company reports second-quarter results. The question is whether revenue growth, defense momentum, and Neutron progress can together justify a triple-digit price-to-sales multiple — or whether the insider exits were a canary in the coal mine. For now, the stock is caught between a record order book and a market that demands perfection.
Ad
Rocket Lab Stock: New Analysis - 3 June
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
